Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Acute and Chronic GVHD: A Deep Dive Into Current Approaches, Near-Term Progress, and Future Directions
  • CME

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: May 4, 2022 Expiration: May 3, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Incyte Corporation
Corey Cutler, MD, MPH, FRCPC
David Miklos, MD, PhD
Robert Zeiser, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review recent advances in our understanding of the underlying pathophysiology of GVHD and the rationale for the use of novel therapies for the treatment of patients with or at risk of developing GVHD
  • Evaluate current and emerging clinical trial data evaluating the use of recently FDA-approved agents for acute, chronic, steroid-naive, or steroid-refractory GVHD
  • Recognize adverse events and toxicities associated with prophylactic strategies and therapeutic approaches and use this information to develop supportive care plans for patients with GVHD
  • Identify patients at risk of GVHD who are candidates for ongoing clinical trials evaluating emerging options for prophylaxis and management

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

David Miklos, MD, PhD

Professor of Medicine
Chief,
Blood Marrow Transplantation and Cancer Cell Therapy
Stanford University
Stanford, California

David Miklos, MD, PhD, has disclosed that he has received funds for research support from Allogene, Adaptive, Kite/Gilead Sciences, and Pharmacyclics and consulting fees from Adaptive, Bristol-Myers Squibb, Janssen, and Novartis.
Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

Corey Cutler, MD, MPH, FRCPC, has disclosed that he has received consulting fees from CareDx, Fresenius Kabi, Incyte, Janssen, Jazz, Kadmon, and Mesoblast and other financial or material support from Omeros.
Robert Zeiser, MD

Professor of Medicine
Department of Hematology and Oncology
Director
Division of Tumor Immunology
Department of Internal Medicine
Freiburg University Medical Center
Freiburg, Germany

Robert Zeiser, MD, has disclosed that he has received consulting fees from Incyte, Mallinckrodt, and Novartis.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer had individual publicly traded stocks/stock options in AstraZeneca.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Taryn O'Loughlin Gross, PhD

Editorial Contributor

Taryn O’Loughlin Gross, PhD, has reported that she has received fees from non-CME services from BTG, Harmony Biosciences, and Salix Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare professionals involved in the management of GVHD.

Goal

The goal of this activity is to improve the knowledge and competence of learners in treating patients with hematologic malignancies with or at risk of developing GVHD.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 04, 2022, through May 03, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Acute and Chronic GVHD: A Deep Dive Into Current Approaches, Near-Term Progress, and Future Directions
  • CME

Loading...
Watch this interactive webcast of a live CCO webinar to learn about recent advances in the management of acute and chronic GVHD.
Corey Cutler, MD, MPH, FRCPC
David Miklos, MD, PhD
Robert Zeiser, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Released: May 4, 2022 Expiration: May 3, 2023

Related Content

Gain expert pharmacist insight on the management of hemophilia A with factor and nonfactor replacement therapies

person default Justin Arnall, PharmD, BCOP person default Kayla Douglas, PharmD Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 24, 2022 Expired: May 23, 2023

Downloadable resource from Clinical Care Options (CCO) to share with patients that covers the basics of hemophilia A and differences between available prophylaxis therapies

Glaivy Batsuli, MD Released: May 9, 2022

GVHD experts address key questions about the treatment of patients with graft versus host disease in this commentary from Clinical Care Options (CCO)

Corey Cutler, MD, MPH, FRCPC Released: May 4, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the management of hemophilia A with nonfactor replacement therapies

person default Kayla Douglas, PharmD Released: April 27, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Incyte Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings